Need professional-grade analysis? Visit stockanalysis.com
$2.98B
10.29
9,400
6.25%
Hikma Pharmaceuticals PLC (HIK) trades on London Stock Exchange in GBX. The company is classified in the Healthcare sector under the Drug Manufacturers - Specialty & Generic industry. The stock currently trades at GBX1379.00, up 2.68% from the previous close.
Over the past year, HIK has traded between a low of GBX1191.00 and a high of GBX2116.24. The stock has lost 25.6% over this period. It is currently 34.8% below its 52-week high.
Hikma Pharmaceuticals PLC has a market capitalization of $2.98B, with a price-to-earnings ratio of 10.29 and a dividend yield of 6.25%.
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The Hikma Rx segment offers oral, respiratory, and other generic and specialty products for the retail market. It provides its products in various therapeutic areas, including respiratory, oncology, and pain management. The company also offers its products in solid, semi-solid, liquid, and injectable dosage forms. It operates in the United Kingdom, Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, United Kingdom.
Side-by-side comparison against top Healthcare peers.